Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...
Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and ...
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Under terms of the deal, Johnson & Johnson will gain an exclusive license to the STAT6 program, with Kaken maintaining commercialization rights in Japan. Johnson & Johnson (J&J) announced that it ...
Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback